Work

Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study

Year: 2014

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-014-0101-x

Authors: Yohann Loriot, Karim Fizazi, Robert J. Jones, Jan Van den Brande, Rhoda L. Molife, Aurelius Omlin, Nicholas D. James, Edwina Baskin-Bey, Marten Heeringa, Benoit Baron, Gertjan M. Holtkamp, Taoufik Ouatas, Johann S. De Bono

Institutions: Université Paris-Sud, Institut Gustave Roussy, Beatson West of Scotland Cancer Centre, University of Glasgow, Antwerp University Hospital, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, University of Birmingham, Astellas Pharma (Netherlands)

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Astellas Pharma Europe, Institut Gustave-Roussy

OpenAlex ID: W1983461177

FWCI: 5.338

Cites: 19

Cited by: 65

Related to: 10